TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Study to Assess the Effect of a Normal vs. High Protein Diets in Carbohydrates Metabolism in Obese Subjects With Diabetes or Prediabetes
Brief Summary: The objective of the study is to assess the effect of low-calorie diets with normal (18%) vs. high (35%) protein (mainly coming from animal source) composition on body weight and carbohydrates metabolism in overweight and obese subjects with pre-diabetes or diabetes. A dietary intervention is carried out during 6 months in 100 subjects who are individually randomized to an energy-restricted diet with two types of macronutrients composition: 1) 35% protein, 30% fat and 35% carbohydrates and 2) 18% protein, 30% fat and 52% carbohydrates. Around 80% of total protein in diet comes from animal source (of whom around 40% from lean red meat). Subjects are provided with weekly menus and different recipes to use them as part of the diet. Monitoring visits with the nutritionist will be performed every 15 days. At the beginning of the study, after 3 and 6 months, the following parameters are determined: anthropometric (weight, waist circumference, body mass index and body composition), blood pressure, dietary (72-hours dietary registry) and exercise and biochemical analysis (total cholesterol, triglycerides, HDL cholesterol, LDL cholesterol, apolipoproteins A1 and B, iron, transferring, ferritin, uric acid, glucose, HbA1c, insulin, adiponectin and resistin). Urine samples are also collected to assess microalbuminuria and ureic nitrogen.


Options:
A: Arm Label: Low Fat Diet + Exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Low Fat Diet plus exercise | Arm Label: Low Carbohydrate Diet + Exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Low Carbohydrate diet + Exercise | Intervention Type: BEHAVIORAL; Name: Low Fat Diet plus exercise; Assigned to Arm(s): Low Fat Diet + Exercise | Intervention Type: BEHAVIORAL; Name: Low Carbohydrate diet + Exercise; Assigned to Arm(s): Low Carbohydrate Diet + Exercise
B: Intervention Type: BEHAVIORAL; Name: Paleolithic diet; Assigned to Arm(s): N/A
C: Arm Label: 18%-Protein diet; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Weight loss interventional study with a low-calorie 18%-protein diet | Arm Label: 35%-Protein diet; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Weight loss interventional study with a low-calorie 35%-protein diet | Intervention Type: BEHAVIORAL; Name: Weight loss interventional study with a low-calorie 18%-protein diet; Assigned to Arm(s): 18%-Protein diet | Intervention Type: BEHAVIORAL; Name: Weight loss interventional study with a low-calorie 35%-protein diet; Assigned to Arm(s): 35%-Protein diet
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: NNR (Nordic Nutrition Recommendations) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: MPD (Modified paleolithic diet) | Intervention Type: BEHAVIORAL; Name: NNR (Nordic Nutrition Recommendations); Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: MPD (Modified paleolithic diet); Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of Efficacy of Denosumab in Patients With Thalassemia Major and Osteoporosis: A Randomized, Placebo-controlled, Single-site, Double Blind Phase 2b Clinical Trial
Brief Summary: This is a single-site, randomized, placebo-controlled, double blind phase 2b clinical trial. Patients with Thalassemia will participate in this study and will be treated with Denosumab or placebo. The effect of Denosumab on lumbar spine BMD in patients with Thalassemia Major and Osteoporosis will be evaluated as compared with control (placebo) at 12 months.


Options:
A: Arm Label: Denosumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Denosumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Denosumab; Assigned to Arm(s): Denosumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: Zoledronic Acid; Assigned to Arm(s): N/A
C: Arm Label: Placebo Capsule; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Arm Label: Zinc (25 mg/d); Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Zinc | Intervention Type: DIETARY_SUPPLEMENT; Name: Zinc; Assigned to Arm(s): Zinc (25 mg/d) | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo Capsule
D: Arm Label: Neridronato; Type: EXPERIMENTAL; Interventions: Drug: Neridronate | Arm Label: Placebo; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Neridronate; Assigned to Arm(s): Neridronato

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Open, Comparative, Within Patient Controlled Multicenter Phase 3 Study of Blue Light Cystoscopy With Cysview and White Light Cystoscopy Using KARL STORZ D-Light C PDD Flexible Videoscope System in Detection of Bladder Cancer in Patients With Bladder Cancer
Brief Summary: The purpose of this study is to investigate if blue light cystoscopy with Cysview improves detection of tumors in patients with bladder cancer during surveillance cystoscopy, using the KARL STORZ D-Light C PDD Flexible Videoscope System. Another purpose is to investigate if Cysview and blue light is safe and effective when used repeatedly.


Options:
A: Arm Label: Resection under blue light; Type: EXPERIMENTAL; Interventions: Other: Endoscopic resection under blue light (Hexvix®) | Arm Label: Resection under white light; Type: ACTIVE_COMPARATOR; Interventions: Other: Endoscopic resection under blue light (Hexvix®) | Intervention Type: OTHER; Name: Endoscopic resection under blue light (Hexvix®); Assigned to Arm(s): Resection under blue light, Resection under white light
B: Arm Label: Standard White Light Cystoscopy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Standard white light cystoscopy | Arm Label: Standard White Light and Hexvix Fluorescence Cystoscopy; Type: EXPERIMENTAL; Interventions: Drug: Hexvix, Procedure: Standard white light cystoscopy | Intervention Type: DRUG; Name: Hexvix; Assigned to Arm(s): Standard White Light and Hexvix Fluorescence Cystoscopy | Intervention Type: PROCEDURE; Name: Standard white light cystoscopy; Assigned to Arm(s): Standard White Light Cystoscopy, Standard White Light and Hexvix Fluorescence Cystoscopy
C: Arm Label: Cysview arm; Type: EXPERIMENTAL; Interventions: Drug: Hexaminolevulinate hydrochloride, Device: KARL STORZ D-Light C PDD Flexible Videoscope System | Intervention Type: DRUG; Name: Hexaminolevulinate hydrochloride; Assigned to Arm(s): Cysview arm | Intervention Type: DEVICE; Name: KARL STORZ D-Light C PDD Flexible Videoscope System; Assigned to Arm(s): Cysview arm
D: Arm Label: Hexvix cystoscopy group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Hexvix | Arm Label: White light; Type: OTHER; Interventions: Other: Standard white light cystoscopy | Intervention Type: DRUG; Name: Hexvix; Assigned to Arm(s): Hexvix cystoscopy group | Intervention Type: OTHER; Name: Standard white light cystoscopy; Assigned to Arm(s): White light

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Feasibility, Safety, and Efficacy of Transendoscopic Enteral Tubing in Fecal Microbiota Transplantation
Brief Summary: No technique by placing a tube through anus into cecum for whole colon administration. This study aimed to evaluate the feasibility, safety, and efficacy of transendoscopic enteral tubing (TET) in fecal microbiota transplantation (FMT) through whole colon.


Options:
A: Arm Label: faecal transplantation; donor faeces; Type: ACTIVE_COMPARATOR; Interventions: Other: treatment with faecal transplantation (donor faeces) | Arm Label: faecal transplantation; placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: treatment with faecal transplantation (own faeces) | Intervention Type: OTHER; Name: treatment with faecal transplantation (donor faeces); Assigned to Arm(s): faecal transplantation; donor faeces | Intervention Type: OTHER; Name: treatment with faecal transplantation (own faeces); Assigned to Arm(s): faecal transplantation; placebo
B: Arm Label: Fecal microbiota transplantation; Type: EXPERIMENTAL; Interventions: Procedure: FMT | Arm Label: Traditional treatments; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: FMT; Assigned to Arm(s): Fecal microbiota transplantation
C: Arm Label: colonoscope via of FMT; Type: N/A; Interventions: Device: colonoscope | Arm Label: Transendoscopic enteral tubing; Type: N/A; Interventions: Device: transendoscopic enteral tubing | Intervention Type: DEVICE; Name: transendoscopic enteral tubing; Assigned to Arm(s): Transendoscopic enteral tubing | Intervention Type: DEVICE; Name: colonoscope; Assigned to Arm(s): colonoscope via of FMT
D: Arm Label: SER-109; Type: EXPERIMENTAL; Interventions: Biological: SER-109 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: BIOLOGICAL; Name: SER-109; Assigned to Arm(s): SER-109 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Primary Prevention of Stroke in Children With Sickle Cell Disease in Sub-Saharan Africa II
Brief Summary: The overall goal of this proposal is to conduct a partial double-blind randomized Phase III clinical trial for primary stroke prevention in children with sickle cell anemia (SCA) in sub-Saharan Africa.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Hydroxyurea, Procedure: Phlebotomy | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Red Cell Transfusions, Procedure: Iron Chelation | Intervention Type: PROCEDURE; Name: Red Cell Transfusions; Assigned to Arm(s): 2 | Intervention Type: PROCEDURE; Name: Iron Chelation; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Hydroxyurea; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Phlebotomy; Assigned to Arm(s): 1
B: Arm Label: Hydroxyurea; Type: ACTIVE_COMPARATOR; Interventions: Drug: Hydroxyurea | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Hydroxyurea; Assigned to Arm(s): Hydroxyurea | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Standard Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Hydroxyurea | Arm Label: Alternative Arm; Type: EXPERIMENTAL; Interventions: Drug: Hydroxyurea | Intervention Type: DRUG; Name: Hydroxyurea; Assigned to Arm(s): Alternative Arm, Standard Arm
D: Arm Label: Moderate Dose Hydroxyurea; Type: ACTIVE_COMPARATOR; Interventions: Drug: Hydroxyurea (Moderate Dose) | Arm Label: Low Dose Hydroxyurea; Type: ACTIVE_COMPARATOR; Interventions: Drug: Hydroxyurea (Low Dose) | Intervention Type: DRUG; Name: Hydroxyurea (Moderate Dose); Assigned to Arm(s): Moderate Dose Hydroxyurea | Intervention Type: DRUG; Name: Hydroxyurea (Low Dose); Assigned to Arm(s): Low Dose Hydroxyurea

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 52-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Ustekinumab in Patients With Moderate-to-Severe Plaque Psoriasis
Brief Summary: The main purpose of this study is to evaluate the efficacy of the study drug ixekizumab compared to ustekinumab in participants with moderate-to-severe-plaque psoriasis.


Options:
A: Arm Label: KHK4827 70mg SC; Type: EXPERIMENTAL; Interventions: Drug: KHK4827 | Arm Label: KHK4827 140mg SC; Type: EXPERIMENTAL; Interventions: Drug: KHK4827 | Arm Label: KHK4827 210mg SC; Type: EXPERIMENTAL; Interventions: Drug: KHK4827 | Arm Label: Placebo SC; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: KHK4827; Assigned to Arm(s): KHK4827 140mg SC, KHK4827 210mg SC, KHK4827 70mg SC | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo SC
B: Intervention Type: DRUG; Name: adalimumab; Assigned to Arm(s): N/A
C: Arm Label: Ustekinumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ustekinumab, Drug: Placebo | Arm Label: Ixekizumab; Type: EXPERIMENTAL; Interventions: Drug: Ixekizumab, Drug: Placebo | Intervention Type: DRUG; Name: Ixekizumab; Assigned to Arm(s): Ixekizumab | Intervention Type: DRUG; Name: Ustekinumab; Assigned to Arm(s): Ustekinumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Ixekizumab, Ustekinumab
D: Arm Label: Ixekizumab; Type: EXPERIMENTAL; Interventions: Drug: Ixekizumab | Arm Label: Guselkumab; Type: EXPERIMENTAL; Interventions: Drug: Guselkumab, Drug: Placebo | Intervention Type: DRUG; Name: Ixekizumab; Assigned to Arm(s): Ixekizumab | Intervention Type: DRUG; Name: Guselkumab; Assigned to Arm(s): Guselkumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Guselkumab

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 52-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Ustekinumab in Patients With Moderate-to-Severe Plaque Psoriasis
Brief Summary: The main purpose of this study is to evaluate the efficacy of the study drug ixekizumab compared to ustekinumab in participants with moderate-to-severe-plaque psoriasis.


Options:
A: Arm Label: Group Adalimumab; Type: EXPERIMENTAL; Interventions: Biological: Adalimumab | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Adalimumab, Other: Placebo | Intervention Type: BIOLOGICAL; Name: Adalimumab; Assigned to Arm(s): Group Adalimumab, Placebo Group | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo Group
B: Arm Label: BI 695501; Type: EXPERIMENTAL; Interventions: Drug: BI 695501 | Arm Label: Humira; Type: ACTIVE_COMPARATOR; Interventions: Drug: Humira | Intervention Type: DRUG; Name: BI 695501; Assigned to Arm(s): BI 695501 | Intervention Type: DRUG; Name: Humira; Assigned to Arm(s): Humira
C: Arm Label: Ustekinumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ustekinumab, Drug: Placebo | Arm Label: Ixekizumab; Type: EXPERIMENTAL; Interventions: Drug: Ixekizumab, Drug: Placebo | Intervention Type: DRUG; Name: Ixekizumab; Assigned to Arm(s): Ixekizumab | Intervention Type: DRUG; Name: Ustekinumab; Assigned to Arm(s): Ustekinumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Ixekizumab, Ustekinumab
D: Arm Label: Risankizumab; Type: EXPERIMENTAL; Interventions: Drug: Risankizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Risankizumab; Assigned to Arm(s): Risankizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Assessment of Thrombotic Status in Patients With Acute Coronary Syndrome
Brief Summary: Impaired thrombotic status is associated with adverse cardiovascular events. Patients with acute coronary syndrome (ACS) are at increased cardiovascular risk. The aim of the study is to determine the usefulness of thrombotic status assessment in a large cohort of ACS patients, managed with contemporary treatments, to identify patients at risk of thrombosis and those at risk of bleeding complications.


Options:
A: Arm Label: Rivaroxaban; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban, Drug: Matching placebo for Rivaroxaban arm (Warfarin placebo) | Arm Label: Warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin, Drug: Matching placebo for Warfarin arm (Rivaroxaban placebo) | Intervention Type: DRUG; Name: Rivaroxaban; Assigned to Arm(s): Rivaroxaban | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin | Intervention Type: DRUG; Name: Matching placebo for Rivaroxaban arm (Warfarin placebo); Assigned to Arm(s): Rivaroxaban | Intervention Type: DRUG; Name: Matching placebo for Warfarin arm (Rivaroxaban placebo); Assigned to Arm(s): Warfarin
B: Arm Label: Stratum 1/ASA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Acetylsalicylic acid, Drug: Clopidogrel | Arm Label: Stratum 1/Rivaroxaban; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban, Drug: Clopidogrel | Arm Label: Stratum 2/ASA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Acetylsalicylic acid, Drug: Ticagrelor | Arm Label: Stratum 2/Rivaroxaban; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban, Drug: Ticagrelor | Intervention Type: DRUG; Name: Acetylsalicylic acid; Assigned to Arm(s): Stratum 1/ASA, Stratum 2/ASA | Intervention Type: DRUG; Name: Rivaroxaban; Assigned to Arm(s): Stratum 1/Rivaroxaban, Stratum 2/Rivaroxaban | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Stratum 1/ASA, Stratum 1/Rivaroxaban | Intervention Type: DRUG; Name: Ticagrelor; Assigned to Arm(s): Stratum 2/ASA, Stratum 2/Rivaroxaban
C: Arm Label: Apixaban; Type: ACTIVE_COMPARATOR; Interventions: Drug: Apixaban | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Apixaban | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Acute Coronary Syndrome; Type: N/A; Interventions: Other: Thrombin generation assays, TEG and GTT | Intervention Type: OTHER; Name: Thrombin generation assays, TEG and GTT; Assigned to Arm(s): Acute Coronary Syndrome

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Reducing Sedentary Behaviour In University Students Using A Text Message-Based Intervention
Brief Summary: The primary purpose of the current study was to determine whether a text message intervention would increase break frequency and length of break from sitting, time spent standing, and time spent in light and moderate intensity physical activity in university students


Options:
A: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: text messages related to sedentary behaviour | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: text messages related to sedentary behaviour; Assigned to Arm(s): Intervention
B: Arm Label: Behavioral intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral intervention to reduce sedentary time delivered via mobile smartphone | Intervention Type: BEHAVIORAL; Name: Behavioral intervention to reduce sedentary time delivered via mobile smartphone; Assigned to Arm(s): Behavioral intervention
C: Arm Label: Control: Lifestyle counseling; Type: ACTIVE_COMPARATOR; Interventions: Other: Control: Lifestyle counseling | Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Other: Intervention group, Other: Control: Lifestyle counseling | Intervention Type: OTHER; Name: Intervention group; Assigned to Arm(s): Intervention group | Intervention Type: OTHER; Name: Control: Lifestyle counseling; Assigned to Arm(s): Control: Lifestyle counseling, Intervention group
D: Arm Label: AP+CP+M; Type: EXPERIMENTAL; Interventions: Behavioral: Action planning, Behavioral: Coping planning, Behavioral: Self-monitoring, Behavioral: Feedback and tips | Arm Label: AP+CP; Type: EXPERIMENTAL; Interventions: Behavioral: Action planning, Behavioral: Coping planning, Behavioral: Feedback and tips | Arm Label: AP+M; Type: EXPERIMENTAL; Interventions: Behavioral: Action planning, Behavioral: Self-monitoring, Behavioral: Feedback and tips | Arm Label: CP+M; Type: EXPERIMENTAL; Interventions: Behavioral: Coping planning, Behavioral: Self-monitoring, Behavioral: Feedback and tips | Arm Label: M; Type: EXPERIMENTAL; Interventions: Behavioral: Self-monitoring, Behavioral: Feedback and tips | Arm Label: CP; Type: EXPERIMENTAL; Interventions: Behavioral: Coping planning, Behavioral: Feedback and tips | Arm Label: AP; Type: EXPERIMENTAL; Interventions: Behavioral: Action planning, Behavioral: Feedback and tips | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Feedback and tips | Intervention Type: BEHAVIORAL; Name: Action planning; Assigned to Arm(s): AP, AP+CP, AP+CP+M, AP+M | Intervention Type: BEHAVIORAL; Name: Coping planning; Assigned to Arm(s): AP+CP, AP+CP+M, CP, CP+M | Intervention Type: BEHAVIORAL; Name: Self-monitoring; Assigned to Arm(s): AP+CP+M, AP+M, CP+M, M | Intervention Type: BEHAVIORAL; Name: Feedback and tips; Assigned to Arm(s): AP, AP+CP, AP+CP+M, AP+M, CP, CP+M, Control, M

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Randomized Open-Label Study of Single Agent Pembrolizumab vs Physicians' Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects With Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus That Have Progressed After First-Line Standard Therapy (KEYNOTE-181)
Brief Summary: In this study, participants with advanced or metastatic adenocarcinoma or squamous cell carcinoma of the esophagus or Siewert type I adenocarcinoma of the esophagogastric junction (EGJ) that had progressed after first-line standard therapy were randomized to receive either pembrolizumab (MK-3475) OR the Investigator's choice of standard chemotherapy with paclitaxel, docetaxel, or irinotecan.

The primary study hypothesis was that treatment with pembrolizumab would prolong overall survival (OS) as compared to treatment with standard chemotherapy.


Options:
A: Arm Label: Ramucirumab (IMC-1211B) Drug Product (DP) and Paclitaxel; Type: EXPERIMENTAL; Interventions: Biological: Ramucirumab (IMC-1211B) DP, Drug: Paclitaxel | Arm Label: Placebo and Paclitaxel; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Paclitaxel | Intervention Type: BIOLOGICAL; Name: Ramucirumab (IMC-1211B) DP; Assigned to Arm(s): Ramucirumab (IMC-1211B) Drug Product (DP) and Paclitaxel | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo and Paclitaxel | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Placebo and Paclitaxel, Ramucirumab (IMC-1211B) Drug Product (DP) and Paclitaxel
B: Intervention Type: DRUG; Name: continuous infusion of 5-fluorouracil; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: combination of irinotecan and cisplatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: oral administration of S-1; Assigned to Arm(s): N/A
C: Arm Label: FOLFIRI plus Ramucirumab; Type: EXPERIMENTAL; Interventions: Drug: FOLFIRI, Drug: Ramucirumab | Arm Label: Paclitaxel plus Ramucirumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ramucirumab, Drug: Paclitaxel | Intervention Type: DRUG; Name: FOLFIRI; Assigned to Arm(s): FOLFIRI plus Ramucirumab | Intervention Type: DRUG; Name: Ramucirumab; Assigned to Arm(s): FOLFIRI plus Ramucirumab, Paclitaxel plus Ramucirumab | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Paclitaxel plus Ramucirumab
D: Arm Label: Pembrolizumab; Type: EXPERIMENTAL; Interventions: Biological: pembrolizumab | Arm Label: Chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: paclitaxel, Drug: docetaxel, Drug: irinotecan | Intervention Type: BIOLOGICAL; Name: pembrolizumab; Assigned to Arm(s): Pembrolizumab | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): Chemotherapy | Intervention Type: DRUG; Name: docetaxel; Assigned to Arm(s): Chemotherapy | Intervention Type: DRUG; Name: irinotecan; Assigned to Arm(s): Chemotherapy

Answer: D